{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Holkova B"],"funding":["NCATS NIH HHS","NCI NIH HHS"],"pagination":["1187-1194"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8106643"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["62(5)"],"pubmed_abstract":["We report the results of a phase 1 dose-escalation study of belinostat and bortezomib in adult patients with acute leukemia or MDS or CML with blast crisis. Thirty-eight patients received IV belinostat days 1-5 and 8-12 with IV bortezomib days 1, 4, 8, and 11 every 21 days. QTc prolongation was the only identified DLT. The RP2Ds were 1.3 mg/m<sup>2</sup> bortezomib and 1000 mg/m<sup>2</sup> belinostat. One patient with highly refractory <i>MLL-ENL</i> rearranged biphenotypic AML with multiple karyotypic aberrations had a complete pathologic and karyotypic response. One patient with post-MPN AML remained on study with stable disease (SD) for 32 cycles. Whole-exome sequencing revealed no aberrations in the first patient and a hyper-mutator genotype in the second. Eighteen patients had a best"],"journal":["Leukemia & lymphoma"],"pubmed_title":["Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome."],"pmcid":["PMC8106643"],"funding_grant_id":["RC2 CA148431","R01 CA205607","P30 CA016059","UL1 TR002649"],"pubmed_authors":["Grant S","Kmieciak M","Dave S","Bandyopadhyay D","Tombes MB","Wan W","Weir C","Collins EB","Garcia-Manero G","Roberts JD","Shrader E","Shafer D","Holkova B","Garnett A","Yazbeck V","Bose P"],"additional_accession":[]},"is_claimable":false,"name":"Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.","description":"We report the results of a phase 1 dose-escalation study of belinostat and bortezomib in adult patients with acute leukemia or MDS or CML with blast crisis. Thirty-eight patients received IV belinostat days 1-5 and 8-12 with IV bortezomib days 1, 4, 8, and 11 every 21 days. QTc prolongation was the only identified DLT. The RP2Ds were 1.3 mg/m<sup>2</sup> bortezomib and 1000 mg/m<sup>2</sup> belinostat. One patient with highly refractory <i>MLL-ENL</i> rearranged biphenotypic AML with multiple karyotypic aberrations had a complete pathologic and karyotypic response. One patient with post-MPN AML remained on study with stable disease (SD) for 32 cycles. Whole-exome sequencing revealed no aberrations in the first patient and a hyper-mutator genotype in the second. Eighteen patients had a best","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2026-05-31T21:54:31.799Z","creation":"2025-02-18T23:32:18.132Z"},"accession":"S-EPMC8106643","cross_references":{"pubmed":["33356689"],"doi":["10.1080/10428194.2020.1861270"]}}